Canagliflozin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Canagliflozin comprises 227 peer-reviewed publications across 15 journals, 21 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, and Heart Failure. Most recent publication: Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial., Diabetologia, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
    Wada T, Mori-Anai K, Takahashi A, et al. · J Diabetes Investig · 2022
    PubMed: PMID 35861630 · NCT03436693 · Diabetes Mellitus, Type 2
  2. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · J Clin Endocrinol Metab · 2024
    PubMed: PMID 37738423 · NCT02891954 · Diabetes Mellitus, Type 2
  3. Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · J Clin Endocrinol Metab · 2025
    PubMed: PMID 38481375 · NCT02891954 · Diabetes Mellitus, Type 2
  4. Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D Status.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · JCEM Case Rep · 2024
    PubMed: PMID 38947416 · NCT02891954 · Diabetes Mellitus, Type 2
  5. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR, Kundu N, Awal HB, et al. · Cardiovasc Diabetol · 2021
    PubMed: PMID 33581737 · NCT02964585 · Diabetes Mellitus, Type 2
  6. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ, Catarig AM, Frias JP, et al. · Diabetologia · 2021
    PubMed: PMID 31897524 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  7. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I, Catarig AM, Frias JP, et al. · Lancet Diabetes Endocrinol · 2020
    PubMed: PMID 31540867 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  8. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Inagaki N, Harashima SI, Kaku K, et al. · Diabetes Obes Metab · 2019
    PubMed: PMID 29110384 · NCT02622113 · Diabetes Mellitus, Type 2

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00968812Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 52
Day 1 (Baseline) and Week 52
Canagliflozin 100 mg-0.82 Percent (±0.039 Standard Error)
Canagliflozin 300 mg-0.93 Percent (±0.039 Standard Error)
Glimepiride-0.81 Percent (±0.039 Standard Error)
NCT01032629
CANVAS
Diabetes Mellitus, Type 2Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke
Up to approximately 8 years
Canagliflozin (Total)26.89 Events per 1000 patient-year
Canagliflozin 100 mg28.41 Events per 1000 patient-year
Canagliflozin 300 mg25.37 Events per 1000 patient-year
Placebo30.36 Events per 1000 patient-year
NCT01064414Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.33 Percent (±0.090 Standard Error)
Canagliflozin 300 mg-0.44 Percent (±0.089 Standard Error)
Placebo-0.03 Percent (±0.090 Standard Error)
NCT01081834Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-2.13 Percent (±0.220 Standard Error)
Canagliflozin 300 mg-2.56 Percent (±0.227 Standard Error)
NCT01081834Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26 (Main Study)
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.77 Percent (±0.065 Standard Error)
Canagliflozin 300 mg-1.03 Percent (±0.064 Standard Error)
Placebo0.14 Percent (±0.065 Standard Error)
NCT01106625Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.85 Percent (±0.075 Standard Error)
Canagliflozin 300 mg-1.06 Percent (±0.076 Standard Error)
Placebo-0.13 Percent (±0.075 Standard Error)
NCT01106651Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.60 Percent (±0.063 Standard Error)
Canagliflozin 300 mg-0.73 Percent (±0.064 Standard Error)
Placebo-0.03 Percent (±0.063 Standard Error)
NCT01106677Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.79 Percent (±0.044 Standard Error)
Canagliflozin 300 mg-0.94 Percent (±0.044 Standard Error)
Placebo/Sitagliptin-0.17 Percent (±0.060 Standard Error)
Sitagliptin 100 mg-0.82 Percent (±0.044 Standard Error)
NCT01106690Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg-0.89 Percent (±0.069 Standard Error)
Canagliflozin 300 mg-1.03 Percent (±0.070 Standard Error)
Placebo/Sitagliptin-0.26 Percent (±0.069 Standard Error)
NCT01137812Diabetes Mellitus, Type 2Change in HbA1c From Baseline to Week 52
Day 1 (Baseline) and Week 52
Canagliflozin 300 mg-1.03 Percent (±0.048 Standard Error)
Sitagliptin 100 mg-0.66 Percent (±0.049 Standard Error)
NCT01381900Diabetes Mellitus, Type 2Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18
Day 1 (Baseline) and Week 18
Canagliflozin 100 mg-0.97 Percent (±0.095 Standard Error)
Canagliflozin 300 mg-1.06 Percent (±0.095 Standard Error)
Placebo-0.47 Percent (±0.096 Standard Error)
NCT01809327Diabetes Mellitus, Type 2Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26
Day 1 (Baseline) and Week 26
Canagliflozin 100 mg + Metformin XR-1.77 percentage of hemoglobin (±0.069 Standard Error)
Canagliflozin 100 Milligram (mg)-1.37 percentage of hemoglobin (±0.071 Standard Error)
Canagliflozin 300 mg-1.42 percentage of hemoglobin (±0.070 Standard Error)
Canagliflozin 300 mg + Metformin XR-1.78 percentage of hemoglobin (±0.070 Standard Error)
Metformin XR-1.30 percentage of hemoglobin (±0.071 Standard Error)
NCT02065791
CREDENCE
Diabetes Mellitus, Type 2Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death
Up to 4.6 years
Canagliflozin 100 mg43.21 Event rate per 1000 participant-years
Placebo61.24 Event rate per 1000 participant-years
NCT02220907Diabetes Mellitus, Type 2Number of Participants With Adverse Events
52 Weeks
Teneligliptin+Canagliflozin11 participants
Teneligliptin+Canagliflozin107 participants
NCT02354222Diabetes Mellitus, Type 2Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)
Baseline, 24 Weeks
Placebo+Canagliflozin0.00 percentage of HbA1c (±0.08 Standard Error)
Teneligliptin+Canagliflozin-0.94 percentage of HbA1c (±0.08 Standard Error)
NCT02354235Diabetes Mellitus, Type 2Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)
Baseline, 24 Weeks
Canagliflozin+Teneligliptin-0.97 percentage of HbA1c (±0.10 Standard Error)
Placebo+Teneligliptin-0.10 percentage of HbA1c (±0.10 Standard Error)
NCT03136484
SUSTAIN 8
Diabetes Mellitus, Type 2Change in HbA1c
Week 0, week 52
Canagliflozin + Semaglutide Placebo-1.0 Percentage (%) of HbA1c (±1.1 Standard Deviation)
Canagliflozin + Semaglutide Placebo-1.0 Percentage (%) of HbA1c (±1.0 Standard Deviation)
Semaglutide + Canagliflozin Placebo-1.7 Percentage (%) of HbA1c (±1.1 Standard Deviation)
Semaglutide + Canagliflozin Placebo-1.5 Percentage (%) of HbA1c (±1.3 Standard Deviation)
NCT03170518Diabetes Mellitus, Type 2Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26
Baseline (Day 1) and Week 26
Canagliflozin 100/300 mg-0.37 Percent (%) of HbA1c (±0.194 Standard Error)
Placebo0.39 Percent (%) of HbA1c (±0.191 Standard Error)
NCT03170518Diabetes Mellitus, Type 2Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)
Canagliflozin 100 mg76.1 Percentage of participants
Canagliflozin 300 mg82.4 Percentage of participants
Placebo74.7 Percentage of participants
NCT03436693Diabetes Mellitus, Type 2Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104
Week 104
Canagliflozin 100mg18.2 Percentage of Participants
Placebo29.5 Percentage of Participants
NCT04252287
CHIEF-HF
Heart FailureChange From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12
Baseline, Week 12
Canagliflozin 100 mg9.2 Score on a scale (±1.27 Standard Error)
Placebo4.9 Score on a scale (±1.27 Standard Error)

Publications by year

1985–2026: 227 publications.

1985
1
1987
1
1996
1
1998
1
2002
1
2003
1
2004
2
2005
5
2006
3
2007
6
2008
4
2009
1
2010
4
2011
3
2012
3
2013
12
2014
12
2015
14
2016
15
2017
14
2018
10
2019
13
2020
11
2021
22
2022
17
2023
21
2024
14
2025
9
2026
6

Publications by indication

Diabetes Mellitus, Type 2 (189)

  • Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.
    Diabetologia · 2026 · PMID 41735586 · NCT05367063
  • Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    J Am Soc Nephrol · 2026 · PMID 41196655 · NCT01032629
  • Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.
    J Am Soc Nephrol · 2026 · PMID 41926219 · NCT02065791
  • Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    J Am Soc Nephrol · 2026 · PMID 40526444 · NCT02065791
  • Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial.
    Diabetologia · 2026 · PMID 41817689 · NCT02065791

Non-alcoholic Fatty Liver Disease (13)

  • Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.
    Obes Sci Pract · 2023 · PMID 30338118 · NCT06256289
  • Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
    Diabetes Obes Metab · 2023 · PMID 34726324 · NCT06256289
  • Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Diabetes Metab · 2021 · PMID 31923578 · NCT06256289
  • Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
    J Endocrinol Invest · 2018 · PMID 28612285 · NCT06256289
  • Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Hum Reprod · 2018 · PMID 27076501 · NCT06256289

Diabetes Mellitus (5)

  • Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas.
    BMJ Open · 2025 · PMID 39971605 · NCT04288778
  • Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
    medRxiv · 2024 · PMID 36993363 · NCT02462421
  • Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
    medRxiv · 2023 · PMID 36945579 · NCT02462421
  • Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
    Circulation · 2021 · PMID 33327727 · NCT03936010
  • Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
    JCI Insight · 2019 · PMID 29669938 · NCT02404870

Heart Failure (5)

  • Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin.
    JACC Heart Fail · 2024 · PMID 38385941 · NCT04252287
  • Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial.
    J Card Fail · 2023 · PMID 37040839 · NCT04252287
  • Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure.
    JACC Heart Fail · 2023 · PMID 37498273 · NCT04252287
  • The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
    Nat Med · 2022 · PMID 35228753 · NCT04252287
  • Novel Trial Design: CHIEF-HF.
    Circ Heart Fail · 2021 · PMID 33724883 · NCT04252287

Diabetes Mellitus, Type 1 (3)

  • The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
    Diabetes Care · 2017 · PMID 27899497 · NCT02139943
  • Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Diabetes Care · 2017 · PMID 26989182 · NCT02139943
  • Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
    Diabetes Care · 2016 · PMID 26486192 · NCT02139943

Polycystic Ovary Syndrome (1)

  • Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Front Endocrinol (Lausanne) · 2022 · PMID 36147577 · NCT04973891

Publications by journal

Trial-results highlights

In studies for type 2 diabetes mellitus, changes in HbA1c from baseline were observed. In NCT00968812, measuring change to week 52, the Canagliflozin 100 mg arm reported a decrease of -0.82 Percent, and the Canagliflozin 300 mg arm reported a decrease of -0.93 Percent. The glimepiride arm showed a change of -0.81 Percent. For changes from baseline to week 26, NCT01064414 reported a decrease of -0.33 Percent for the Canagliflozin 100 mg arm and -0.44 Percent for the Canagliflozin 300 mg arm, compared to -0.03 Percent for placebo. In NCT01081834 (Main Study), the Canagliflozin 100 mg arm showed a change of -0.77 Percent, and the Canagliflozin 300 mg arm showed a change of -1.03 Percent, while the placebo arm showed a change of 0.14 Percent.

Further investigations into HbA1c changes from baseline to week 26 include NCT01106625, where the Canagliflozin 100 mg arm had a change of -0.85 Percent and the Canagliflozin 300 mg arm had a change of -1.06 Percent. The placebo arm reported -0.13 Percent. In NCT01106651, the Canagliflozin 100 mg arm showed a change of -0.60 Percent, and the Canagliflozin 300 mg arm showed a change of -0.73 Percent, compared to -0.03 Percent for placebo. In NCT01106677, the Canagliflozin 100 mg arm had a change of -0.79 Percent, and the Canagliflozin 300 mg arm had a change of -0.94 Percent. The sitagliptin 100 mg arm reported -0.82 Percent, and the placebo/sitagliptin arm reported -0.17 Percent. A high glycemic substudy within NCT01081834 reported a change in HbA1c of -2.13 Percent for the Canagliflozin 100 mg arm and -2.56 Percent for the Canagliflozin 300 mg arm.

For major adverse cardiovascular events (MACE) in type 2 diabetes mellitus, the CANVAS study (NCT01032629) tracked events over approximately 8 years. The Canagliflozin (Total) arm reported 26.89 Events per 1000 patient-year. The Canagliflozin 100 mg arm reported 28.41 Events per 1000 patient-year, and the Canagliflozin 300 mg arm reported 25.37 Events per 1000 patient-year. The placebo arm reported 30.36 Events per 1000 patient-year. All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Canagliflozin publications (227)

2026 (6 papers)

  1. Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial.
    Yan H, Liu J, Zhang Z, et al. · Diabetologia · 2026 · Derived
    PubMed: PMID 41735586 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  2. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    Mottl A, Scott C, Green JB, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41196655 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  3. Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.
    Moedt E, Koshino A, Jongs N, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41926219 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  4. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    Jongs N, Gasparyan SB, Frison L, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40526444 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  5. Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial.
    Chiriacò M, Tricò D, Giannoni A, et al. · Diabetologia · 2026 · Derived
    PubMed: PMID 41817689 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  6. Impact of canagliflozin on heart stress and outcomes: Pooled insights from CREDENCE and CANVAS.
    Bayes-Genis A, Cai A, Liu Y, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 40689549 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2

2025 (9 papers)

  1. Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · J Clin Endocrinol Metab · 2025 · Trial result
    PubMed: PMID 38481375 · NCT02891954 · Diabetes Mellitus, Type 2
  2. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.
    Oshima M, Buizen L, Jongs N, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40658498 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  3. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.
    Nguyen TN, Yu J, Perkovic V, et al. · J Am Geriatr Soc · 2025 · Derived
    PubMed: PMID 40105285 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  4. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
    Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39963952 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  5. Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.
    Nadgir U, Ali SR, Gogate J, et al. · Ann Intern Med · 2025 · Derived
    PubMed: PMID 40759025 · NCT03170518 · Diabetes Mellitus, Type 2
  6. Climate footprint of industry-sponsored in-human clinical trials: life cycle assessments of clinical trials spanning multiple phases and disease areas.
    LaRoche JK, Lanier J, Alvarenga R, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 39971605 · NCT04288778 · Diabetes Mellitus
  7. A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.
    Januzzi JLJ, Sattar N, Vaduganathan M, et al. · Cardiovasc Diabetol · 2025 · Derived
    PubMed: PMID 40375260 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  8. Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females.
    Doi Y, Hamano T, Yamaguchi O, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40239057 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  9. Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.
    Chatur S, Vaduganathan M, Fletcher RA, et al. · Eur J Heart Fail · 2025 · Derived
    PubMed: PMID 39844714 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2

2024 (14 papers)

  1. Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · J Clin Endocrinol Metab · 2024 · Trial result
    PubMed: PMID 37738423 · NCT02891954 · Diabetes Mellitus, Type 2
  2. Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D Status.
    Shahidzadeh Yazdi Z, Streeten EA, Whitlatch HB, et al. · JCEM Case Rep · 2024 · Trial result
    PubMed: PMID 38947416 · NCT02891954 · Diabetes Mellitus, Type 2
  3. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.
    Yuan T, Liu S, Dong Y, et al. · Diabetol Metab Syndr · 2024 · Derived
    PubMed: PMID 33117454 · NCT04014192 · Diabetes Mellitus, Type 2
  4. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
    Willis M, Nilsson A, Kellerborg K, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 33263893 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  5. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.
    Willis M, Asseburg C, Slee A, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 32930969 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  6. Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial.
    Vaduganathan M, Cannon CP, Jardine MJ, et al. · Eur J Heart Fail · 2024 · Derived
    PubMed: PMID 38932575 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  7. Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness.
    Taylor SI, Montasser ME, Yuen AH, et al. · medRxiv · 2024 · Derived
    PubMed: PMID 36993363 · NCT02462421 (SGLT2iPGx) · Diabetes Mellitus
  8. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
    Sharma A, Razaghizad A, Joury A, et al. · J Am Heart Assoc · 2024 · Derived
    PubMed: PMID 38240199 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  9. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P, Tunnicliffe DJ, Toyama T, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38770818 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  10. Associations of Angiopoietin 2 and Vascular Endothelial Growth Factor-A Concentrations with Clinical End Points.
    Mohebi R, Liu Y, Hansen MK, et al. · Clin J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 38099944 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  11. Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin.
    Mohebi R, Jones PG, Spertus JA, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 38385941 · NCT04252287 (CHIEF-HF) · Heart Failure
  12. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Jardine MJ, Mahaffey KW, Neal B, et al. · Am J Nephrol · 2024 · Derived
    PubMed: PMID 29253846 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  13. Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
    Januzzi JL, Liu Y, Sattar N, et al. · Am Heart J · 2024 · Derived
    PubMed: PMID 38401646 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  14. Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy.
    Durkin M, Blais J · Diabetes Ther · 2024 · Derived
    PubMed: PMID 33340064 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2

2023 (21 papers)

  1. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
    Yu J, Sweeting AN, Gianacas C, et al. · Diabetes Obes Metab · 2023 · Derived
    PubMed: PMID 37671609 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  2. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
    Yi TW, Smyth B, Di Tanna GL, et al. · Am J Kidney Dis · 2023 · Derived
    PubMed: PMID 36889425 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  3. Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
    van der Hoek S, Jongs N, Oshima M, et al. · Clin J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 36999981 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  4. Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
    Taylor SI, Cherng HR, Yazdi ZS, et al. · medRxiv · 2023 · Derived
    PubMed: PMID 36945579 · NCT02462421 (SGLT2iPGx) · Diabetes Mellitus
  5. Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.
    Taylor SI, Cherng HR, Shahidzadeh Yazdi Z, et al. · Diabetes Obes Metab · 2023 · Derived
    PubMed: PMID 37608471 · NCT02891954 · Diabetes Mellitus, Type 2
  6. Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.
    Shields BM, Dennis JM, Angwin CD, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36477733 · NCT02653209 (TriMaster) · Diabetes Mellitus, Type 2
  7. Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
    Shields BM, Angwin CD, Shepherd MH, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36477734 · NCT02653209 (TriMaster) · Diabetes Mellitus, Type 2
  8. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
    Sen T, Ju W, Nair V, et al. · Kidney Int · 2023 · Derived
    PubMed: PMID 37543256 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  9. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
    Pulleyblank R, Larsen NB · Pharmacoecon Open · 2023 · Derived
    PubMed: PMID 37178435 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  10. Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial.
    Nassif M, Birmingham MC, Lanfear DE, et al. · J Card Fail · 2023 · Derived
    PubMed: PMID 37040839 · NCT04252287 (CHIEF-HF) · Heart Failure
  11. Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
    Mohebi R, Liu Y, Hansen MK, et al. · Cardiovasc Diabetol · 2023 · Derived
    PubMed: PMID 37438734 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  12. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
    Lee SWH, Chen WS, Sellappans R, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37435938 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  13. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
    Januzzi JL, Mohebi R, Liu Y, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37603600 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  14. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
    Heerspink HJL, Jongs N, Schloemer P, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 37872654 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  15. Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure.
    Golbus JR, Gosch K, Birmingham MC, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 37498273 · NCT04252287 (CHIEF-HF) · Heart Failure
  16. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA, Jongs N, Chertow GM, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 37876229 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  17. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
    Fletcher RA, Arnott C, Rockenschaub P, et al. · J Am Heart Assoc · 2023 · Derived
    PubMed: PMID 37345834 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  18. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.
    Ferrannini G, Pollock C, Natali A, et al. · Cardiovasc Diabetol · 2023 · Derived
    PubMed: PMID 37120538 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  19. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.
    Borisov AN, Kutz A, Christ ER, et al. · J Clin Endocrinol Metab · 2023 · Derived
    PubMed: PMID 37149821 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  20. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.
    Itani T, Ishihara T · Obes Sci Pract · 2023 · Background
    PubMed: PMID 30338118 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  21. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
    Cai M, Shao X, Xing F, et al. · Diabetes Obes Metab · 2023 · Background
    PubMed: PMID 34726324 · NCT06256289 · Non-alcoholic Fatty Liver Disease

2022 (17 papers)

  1. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
    Wada T, Mori-Anai K, Takahashi A, et al. · J Diabetes Investig · 2022 · Trial result
    PubMed: PMID 35861630 · NCT03436693 · Diabetes Mellitus, Type 2
  2. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z, Jardine MJ, Li Q, et al. · Stroke · 2022 · Derived
    PubMed: PMID 33874750 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  3. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
    Zhang J, Xing C, Cheng X, et al. · Front Endocrinol (Lausanne) · 2022 · Derived
    PubMed: PMID 36147577 · NCT04973891 · Polycystic Ovary Syndrome
  4. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
    Yu J, Li J, Leaver PJ, et al. · Cardiovasc Res · 2022 · Derived
    PubMed: PMID 33826709 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  5. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program.
    Young TK, Li JW, Kang A, et al. · Diabetologia · 2022 · Derived
    PubMed: PMID 34448033 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  6. Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease.
    Waijer SW, Sen T, Arnott C, et al. · Clin J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 34876454 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  7. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    Vaduganathan M, Sattar N, Xu J, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 35115099 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  8. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
    Spertus JA, Birmingham MC, Nassif M, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35228753 · NCT04252287 (CHIEF-HF) · Heart Failure
  9. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
    Sarraju A, Bakris G, Cannon CP, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 36302584 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  10. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.
    Rasmussen DGK, Hansen MK, Blair J, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 36443792 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  11. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.
    Qiu R, Capuano G, Meininger G, et al. · J Clin Transl Endocrinol · 2022 · Derived
    PubMed: PMID 29159083 · NCT01340664 · Diabetes Mellitus, Type 2
  12. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program.
    Nunes JC, Yu J, Arnott C, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35938182 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  13. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
    Li JW, Arnott C, Heerspink HJL, et al. · J Am Heart Assoc · 2022 · Derived
    PubMed: PMID 35929472 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  14. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M, Zhou Z, Lambers Heerspink HJ, et al. · Clin J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 33619120 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  15. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL, Oshima M, Zhang H, et al. · Am J Kidney Dis · 2022 · Derived
    PubMed: PMID 34029680 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  16. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
    Ferrannini E, Baldi S, Scozzaro T, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35724306 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  17. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
    Charytan DM, Yu J, Jardine MJ, et al. · Clin J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 35063969 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2

2021 (22 papers)

  1. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR, Kundu N, Awal HB, et al. · Cardiovasc Diabetol · 2021 · Trial result
    PubMed: PMID 33581737 · NCT02964585 · Diabetes Mellitus, Type 2
  2. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
    McCrimmon RJ, Catarig AM, Frias JP, et al. · Diabetologia · 2021 · Trial result
    PubMed: PMID 31897524 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  3. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
    Yu J, Arnott C, Neuen BL, et al. · ESC Heart Fail · 2021 · Derived
    PubMed: PMID 33595905 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  4. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
    Ye N, Jardine MJ, Oshima M, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33554616 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  5. Novel Trial Design: CHIEF-HF.
    Spertus JA, Birmingham MC, Butler J, et al. · Circ Heart Fail · 2021 · Derived
    PubMed: PMID 33724883 · NCT04252287 (CHIEF-HF) · Heart Failure
  6. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
    Sarraju A, Li J, Cannon CP, et al. · Am Heart J · 2021 · Derived
    PubMed: PMID 33358942 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  7. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
    Powell DR, Zambrowicz B, Morrow L, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 31837264 · NCT01916863
  8. Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.
    Oshima M, Neal B, Toyama T, et al. · J Am Soc Nephrol · 2021 · Derived
    PubMed: PMID 32694216 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  9. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL, Ohkuma T, Neal B, et al. · Am J Kidney Dis · 2021 · Derived
    PubMed: PMID 32971190 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  10. Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
    Matthews DR, Wysham C, Davies M, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 32691499 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  11. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I, Capehorn MS, Catarig AM, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 32827435 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  12. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
    Li J, Woodward M, Perkovic V, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 31676303 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  13. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL, Xu J, Li J, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 33121714 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  14. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
    Januzzi JL, Butler J, Sattar N, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33158949 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  15. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
    Franklin JM, Patorno E, Desai RJ, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33327727 · NCT03936010 · Diabetes Mellitus
  16. TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol.
    Angwin C, Jenkinson C, Jones A, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33371044 · NCT02653209 (TriMaster) · Diabetes Mellitus, Type 2
  17. Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes.
    Ali AM, Martinez R, Al-Jobori H, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32220916 · NCT02324842 · Diabetes Mellitus, Type 2
  18. Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.
    Ali AM, Mari A, Martinez R, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 32745202 · NCT02324842 · Diabetes Mellitus, Type 2
  19. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
    Singh JSS, Mordi IR, Vickneson K, et al. · Diabetes Care · 2021 · Background
    PubMed: PMID 32245746 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  20. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, et al. · Diabetes Metab · 2021 · Background
    PubMed: PMID 31923578 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  21. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, et al. · Circulation · 2021 · Background
    PubMed: PMID 33186500 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  22. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
    Brown AJM, Gandy S, McCrimmon R, et al. · Eur Heart J · 2021 · Background
    PubMed: PMID 32578850 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2

2020 (11 papers)

  1. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I, Catarig AM, Frias JP, et al. · Lancet Diabetes Endocrinol · 2020 · Trial result
    PubMed: PMID 31540867 · NCT03136484 (SUSTAIN 8) · Diabetes Mellitus, Type 2
  2. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z, Jardine M, Perkovic V, et al. · Diabetologia · 2020 · Derived
    PubMed: PMID 31399845 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  3. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW, Jardine MJ, Bompoint S, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31291786 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  4. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
    Jardine MJ, Zhou Z, Mahaffey KW, et al. · J Am Soc Nephrol · 2020 · Derived
    PubMed: PMID 32354987 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  5. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
    Heerspink HJL, Perco P, Mulder S, et al. · Diabetologia · 2020 · Derived
    PubMed: PMID 31001673 · NCT00968812 · Diabetes Mellitus, Type 2
  6. Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
    Gilbert RE, Mende C, Vijapurkar U, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 28197834 · NCT01081834 · Diabetes Mellitus, Type 2
  7. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
    Figtree GA, Rådholm K, Barrett TD, et al. · Circulation · 2020 · Derived
    PubMed: PMID 30882240 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  8. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
    Cannon CP, Perkovic V, Agarwal R, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31707795 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  9. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S, Mazer CD, Yan AT, et al. · Circulation · 2020 · Background
    PubMed: PMID 31434508 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  10. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
    Saeedi P, Petersohn I, Salpea P, et al. · Diabetes Res Clin Pract · 2020 · Background
    PubMed: PMID 31518657 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  11. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.
    Dunlay SM, Givertz MM, Aguilar D, et al. · Circulation · 2020 · Background
    PubMed: PMID 31167558 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2

2019 (13 papers)

  1. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
    Inagaki N, Harashima SI, Kaku K, et al. · Diabetes Obes Metab · 2019 · Trial result
    PubMed: PMID 29110384 · NCT02622113 · Diabetes Mellitus, Type 2
  2. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
    Harashima SI, Inagaki N, Kondo K, et al. · Diabetes Obes Metab · 2019 · Trial result
    PubMed: PMID 29473709 · NCT02227849 · Diabetes Mellitus, Type 2
  3. Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
    Zhou Z, Lindley RI, Rådholm K, et al. · Stroke · 2019 · Derived
    PubMed: PMID 30591006 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  4. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET, Eudicone JM, Bell KF, et al. · Am J Manag Care · 2019 · Derived
    PubMed: PMID 29693360 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  5. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K, Figtree G, Perkovic V, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29526832 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  6. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V, Jardine MJ, Neal B, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 30990260 · NCT02065791 (CREDENCE) · Diabetes Mellitus, Type 2
  7. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V, de Zeeuw D, Mahaffey KW, et al. · Lancet Diabetes Endocrinol · 2019 · Derived
    PubMed: PMID 29937267 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  8. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL, Ohkuma T, Neal B, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29941478 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  9. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW, Neal B, Perkovic V, et al. · Circulation · 2019 · Derived
    PubMed: PMID 29133604 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  10. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
    Garvey WT, Van Gaal L, Leiter LA, et al. · Metabolism · 2019 · Derived
    PubMed: PMID 29452178 · NCT00968812 · Diabetes Mellitus, Type 2
  11. Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
    Blau JE, Bauman V, Conway EM, et al. · JCI Insight · 2019 · Derived
    PubMed: PMID 29669938 · NCT02404870 · Diabetes Mellitus
  12. Adverse effects of SGLT2 inhibitors on bone health.
    Blau JE, Taylor SI · Nat Rev Nephrol · 2019 · Background
    PubMed: PMID 29875481 · NCT02891954 · Diabetes Mellitus, Type 2
  13. Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
    Beitelshees AL, Leslie BR, Taylor SI, et al. · Diabetes · 2019 · Background
    PubMed: PMID 31109940 · NCT02891954 · Diabetes Mellitus, Type 2

2018 (10 papers)

  1. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T, Inagaki N, Kondo K, et al. · Diabetes Obes Metab · 2018 · Trial result
    PubMed: PMID 28608617 · NCT02220907 · Diabetes Mellitus, Type 2
  2. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T, Inagaki N, Kondo K, et al. · Diabetes Obes Metab · 2018 · Trial result
    PubMed: PMID 28177187 · NCT02354235 · Diabetes Mellitus, Type 2
  3. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T, Inagaki N, Kondo K, et al. · Diabetes Obes Metab · 2018 · Trial result
    PubMed: PMID 28786530 · NCT02354222 · Diabetes Mellitus, Type 2
  4. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF, Xie J, Sherman SE, et al. · Clin Ther · 2018 · Derived
    PubMed: PMID 29103664 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  5. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
    Devineni D, Murphy J, Wang SS, et al. · Clin Pharmacol Drug Dev · 2018 · Derived
    PubMed: PMID 27136910 · NCT01157000
  6. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
    Devineni D, Manitpisitkul P, Murphy J, et al. · Clin Pharmacol Drug Dev · 2018 · Derived
    PubMed: PMID 27136908 · NCT01340677
  7. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D, Manitpisitkul P, Murphy J, et al. · Clin Pharmacol Drug Dev · 2018 · Derived
    PubMed: PMID 27140803 · NCT01273571
  8. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.
    Cai J, Delahanty LM, Akapame S, et al. · Patient · 2018 · Derived
    PubMed: PMID 29313267 · NCT01106625 · Diabetes Mellitus, Type 2
  9. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
    Rocha ALL, Faria LC, Guimarães TCM, et al. · J Endocrinol Invest · 2018 · Background
    PubMed: PMID 28612285 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  10. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D, Tziomalos K, Božić-Antić I, et al. · Hum Reprod · 2018 · Background
    PubMed: PMID 27076501 · NCT06256289 · Non-alcoholic Fatty Liver Disease

2017 (14 papers)

  1. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
    Inagaki N, Harashima S, Maruyama N, et al. · Cardiovasc Diabetol · 2017 · Trial result
    PubMed: PMID 27316668 · NCT02220920 · Diabetes Mellitus, Type 2
  2. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G, Lavalle-González FJ, Davidson JA, et al. · Postgrad Med · 2017 · Derived
    PubMed: PMID 27391951 · NCT01106677 · Diabetes Mellitus, Type 2
  3. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
    Rodbard HW, Peters AL, Slee A, et al. · Diabetes Care · 2017 · Derived
    PubMed: PMID 27899497 · NCT02139943 · Diabetes Mellitus, Type 1
  4. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
    Qiu R, Balis D, Xie J, et al. · Curr Med Res Opin · 2017 · Derived
    PubMed: PMID 27977934 · NCT01106690 · Diabetes Mellitus, Type 2
  5. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M, Townsend RR, Davies MJ, et al. · Cardiovasc Diabetol · 2017 · Derived
    PubMed: PMID 28241822 · NCT01081834 · Diabetes Mellitus, Type 2
  6. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL, Henry RR, Thakkar P, et al. · Diabetes Care · 2017 · Derived
    PubMed: PMID 26989182 · NCT02139943 · Diabetes Mellitus, Type 1
  7. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
    Patel CA, Bailey RA, Vijapurkar U, et al. · BMC Health Serv Res · 2017 · Derived
    PubMed: PMID 27495291 · NCT00968812 · Diabetes Mellitus, Type 2
  8. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Mahaffey KW, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28605608 · NCT01989754 (CANVAS-R) · Diabetes Mellitus, Type 2
  9. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
    John M, Cerdas S, Violante R, et al. · Int J Clin Pract · 2017 · Derived
    PubMed: PMID 27600862 · NCT01106677 · Diabetes Mellitus, Type 2
  10. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL, Butler J, Jarolim P, et al. · J Am Coll Cardiol · 2017 · Derived
    PubMed: PMID 28619659 · NCT01106651 · Diabetes Mellitus, Type 2
  11. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ, Merton K, Vijapurkar U, et al. · Cardiovasc Diabetol · 2017 · Derived
    PubMed: PMID 28327140 · NCT01106625 · Diabetes Mellitus, Type 2
  12. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Blonde L, Stenlöf K, Fung A, et al. · Postgrad Med · 2017 · Derived
    PubMed: PMID 27002421 · NCT00968812 · Diabetes Mellitus, Type 2
  13. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome.
    Makri E, Tziomalos K · Minerva Endocrinol · 2017 · Background
    PubMed: PMID 27792214 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  14. Metabolic syndrome, diet and exercise.
    De Sousa SM, Norman RJ · Best Pract Res Clin Obstet Gynaecol · 2017 · Background
    PubMed: PMID 26972165 · NCT06256289 · Non-alcoholic Fatty Liver Disease

2016 (15 papers)

  1. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB, Bilezikian JP, Usiskin K, et al. · J Clin Endocrinol Metab · 2016 · Derived
    PubMed: PMID 26580237 · NCT01106677 · Diabetes Mellitus, Type 2
  2. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.
    Rosenstock J, Chuck L, González-Ortiz M, et al. · Diabetes Care · 2016 · Derived
    PubMed: PMID 26786577 · NCT01809327 · Diabetes Mellitus, Type 2
  3. Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
    Leiter LA, Langslet G, Vijapurkar U, et al. · Diabetes Ther · 2016 · Derived
    PubMed: PMID 26984361 · NCT00968812 · Diabetes Mellitus, Type 2
  4. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ, Eliaschewitz FG, Cerdas S, et al. · Curr Med Res Opin · 2016 · Derived
    PubMed: PMID 26579834 · NCT01081834 · Diabetes Mellitus, Type 2
  5. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.
    Henry RR, Thakkar P, Tong C, et al. · Diabetes Care · 2016 · Derived
    PubMed: PMID 26486192 · NCT02139943 · Diabetes Mellitus, Type 1
  6. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
    Gavin JR, Davies MJ, Davies M, et al. · Curr Med Res Opin · 2016 · Derived
    PubMed: PMID 26121561 · NCT01106690 · Diabetes Mellitus, Type 2
  7. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
    Devineni D, Polidori D, Curtin C, et al. · Clin Ther · 2016 · Derived
    PubMed: PMID 26687552 · NCT01748526
  8. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D, Curtin CR, Marbury TC, et al. · Clin Ther · 2016 · Derived
    PubMed: PMID 25659911 · NCT01186588 · Hepatic Insufficiency
  9. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Chen X, Hu P, Vaccaro N, et al. · Clin Ther · 2016 · Derived
    PubMed: PMID 26048186 · NCT01707316
  10. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
    Cefalu WT, Stenlöf K, Leiter LA, et al. · Diabetologia · 2016 · Derived
    PubMed: PMID 25813214 · NCT01106690 · Diabetes Mellitus, Type 2
  11. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
    Blonde L, Woo V, Mathieu C, et al. · Curr Med Res Opin · 2016 · Derived
    PubMed: PMID 26373629 · NCT01106625 · Diabetes Mellitus, Type 2
  12. Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
    Bilezikian JP, Watts NB, Usiskin K, et al. · J Clin Endocrinol Metab · 2016 · Derived
    PubMed: PMID 26580234 · NCT01106651 · Diabetes Mellitus, Type 2
  13. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
    Bailey RA, Vijapurkar U, Meininger G, et al. · Clin Ther · 2016 · Derived
    PubMed: PMID 25795432 · NCT01106677 · Diabetes Mellitus, Type 2
  14. Possible adverse effects of SGLT2 inhibitors on bone.
    Taylor SI, Blau JE, Rother KI, et al. · Lancet Diabetes Endocrinol · 2016 · Background
    PubMed: PMID 25523498 · NCT02891954 · Diabetes Mellitus, Type 2
  15. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
    Erondu N, Desai M, Ways K, et al. · Diabetes Care · 2016 · Background
    PubMed: PMID 26203064 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

2015 (14 papers)

  1. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
    Weir MR, Kline I, Xie J, et al. · Curr Med Res Opin · 2015 · Derived
    PubMed: PMID 24786834 · NCT01081834 · Diabetes Mellitus, Type 2
  2. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
    Weir MR, Januszewicz A, Gilbert RE, et al. · J Clin Hypertens (Greenwich) · 2015 · Derived
    PubMed: PMID 25329038 · NCT01081834 · Diabetes Mellitus, Type 2
  3. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K, Cefalu WT, Kim KA, et al. · Curr Med Res Opin · 2015 · Derived
    PubMed: PMID 24073995 · NCT01081834 · Diabetes Mellitus, Type 2
  4. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Nyirjesy P, Sobel JD, Fung A, et al. · Curr Med Res Opin · 2015 · Derived
    PubMed: PMID 24517339 · NCT01106625 · Diabetes Mellitus, Type 2
  5. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B, Perkovic V, de Zeeuw D, et al. · Diabetes Care · 2015 · Derived
    PubMed: PMID 25468945 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  6. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA, Yoon KH, Arias P, et al. · Diabetes Care · 2015 · Derived
    PubMed: PMID 25205142 · NCT00968812 · Diabetes Mellitus, Type 2
  7. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Fulcher G, Matthews DR, Perkovic V, et al. · Diabetes Ther · 2015 · Derived
    PubMed: PMID 26081793 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  8. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D, Vaccaro N, Polidori D, et al. · Clin Ther · 2015 · Derived
    PubMed: PMID 24726680 · NCT01294631
  9. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
    Devineni D, Polidori D, Curtin CR, et al. · Int J Clin Pharmacol Ther · 2015 · Derived
    PubMed: PMID 25907176 · NCT01286103
  10. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D, Manitpisitkul P, Vaccaro N, et al. · Int J Clin Pharmacol Ther · 2015 · Derived
    PubMed: PMID 25345427 · NCT01714206
  11. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Wanner C, Lachin JM, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26378978 · NCT02964585 · Diabetes Mellitus, Type 2
  12. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI, Blau JE, Rother KI, et al. · J Clin Endocrinol Metab · 2015 · Background
    PubMed: PMID 26086329 · NCT02891954 · Diabetes Mellitus, Type 2
  13. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
    Oliva RV, Bakris GL · J Am Soc Hypertens · 2015 · Background
    PubMed: PMID 24631482 · NCT02964585 · Diabetes Mellitus, Type 2
  14. Association of Cardiometabolic Multimorbidity With Mortality.
    Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. · JAMA · 2015 · Background
    PubMed: PMID 26151266 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2

2014 (12 papers)

  1. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K, Kline I, Fung A, et al. · Postgrad Med · 2014 · Derived
    PubMed: PMID 24918789 · NCT01106677 · Diabetes Mellitus, Type 2
  2. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
    Stein P, Berg JK, Morrow L, et al. · Metabolism · 2014 · Derived
    PubMed: PMID 25110280 · NCT01381887 · Diabetes Mellitus, Type 2
  3. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
    Sinclair A, Bode B, Harris S, et al. · BMC Endocr Disord · 2014 · Derived
    PubMed: PMID 24742013 · NCT01106690 · Diabetes Mellitus, Type 2
  4. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
    Schernthaner G, Gross JL, Rosenstock J, et al. · Diabetes Care · 2014 · Derived
    PubMed: PMID 23564919 · NCT01137812 · Diabetes Mellitus, Type 2
  5. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
    Polidori D, Sha S, Mudaliar S, et al. · Diabetes Care · 2014 · Derived
    PubMed: PMID 23412078 · NCT01173549
  6. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
    Polidori D, Mari A, Ferrannini E, et al. · Diabetologia · 2014 · Derived
    PubMed: PMID 24585202 · NCT01081834 · Diabetes Mellitus, Type 2
  7. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ, Januszewicz A, Davidson J, et al. · Diabetologia · 2014 · Derived
    PubMed: PMID 24026211 · NCT01106677 · Diabetes Mellitus, Type 2
  8. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
    Stanton RC · Circulation · 2014 · Background
    PubMed: PMID 24334174 · NCT02964585 · Diabetes Mellitus, Type 2
  9. Evaluating the Effect of Ramadan Fasting on Muslim Patients with Diabetes in relation to Use of Medication and Lifestyle Patterns: A Prospective Study.
    Siaw MY, Chew DE, Dalan R, et al. · Int J Endocrinol · 2014 · Background
    PubMed: PMID 25435876 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  10. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    He YL, Foteinos G, Neelakantham S, et al. · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 23782529 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  11. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
    Brady EM, Davies MJ, Gray LJ, et al. · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 24373063 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  12. Standards of medical care in diabetes--2014.
    American Diabetes Association · Diabetes Care · 2014 · Background
    PubMed: PMID 24357209 · NCT02964585 · Diabetes Mellitus, Type 2

2013 (12 papers)

  1. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
    Polidori D, Sha S, Ghosh A, et al. · J Clin Endocrinol Metab · 2013 · Derived
    PubMed: PMID 23585665 · NCT01273558 · Diabetes Mellitus, Type 2
  2. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P, Zhao Y, Ways K, et al. · Curr Med Res Opin · 2013 · Derived
    PubMed: PMID 22632452 · NCT00642278 · Diabetes Mellitus, Type 2
  3. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE, Capuano G, Ways K, et al. · Curr Med Res Opin · 2013 · Derived
    PubMed: PMID 22548646 · NCT00642278 · Diabetes Mellitus, Type 2
  4. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
    Neal B, Perkovic V, de Zeeuw D, et al. · Am Heart J · 2013 · Derived
    PubMed: PMID 23895803 · NCT01032629 (CANVAS) · Diabetes Mellitus, Type 2
  5. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Cefalu WT, Leiter LA, Yoon KH, et al. · Lancet · 2013 · Derived
    PubMed: PMID 23850055 · NCT00968812 · Diabetes Mellitus, Type 2
  6. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B, Stenlöf K, Sullivan D, et al. · Hosp Pract (1995) · 2013 · Derived
    PubMed: PMID 23680739 · NCT01106651 · Diabetes Mellitus, Type 2
  7. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF, Bakris G, Cariou B, et al. · Diabetes Obes Metab · 2013 · Background
    PubMed: PMID 23464594 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  8. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K, Cefalu WT, Kim KA, et al. · Diabetes Obes Metab · 2013 · Background
    PubMed: PMID 23279307 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  9. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
    Seaquist ER, Anderson J, Childs B, et al. · Diabetes Care · 2013 · Background
    PubMed: PMID 23589542 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  10. Increased mortality of patients with diabetes reporting severe hypoglycemia.
    McCoy RG, Van Houten HK, Ziegenfuss JY, et al. · Diabetes Care · 2013 · Background
    PubMed: PMID 22699297 · NCT02624908 · Diabetes Mellitus, Type 2
  11. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
    Ferrannini E, Solini A · Nat Rev Endocrinol · 2013 · Background
    PubMed: PMID 22310849 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  12. Kidney disease and increased mortality risk in type 2 diabetes.
    Afkarian M, Sachs MC, Kestenbaum B, et al. · J Am Soc Nephrol · 2013 · Background
    PubMed: PMID 23362314 · NCT02964585 · Diabetes Mellitus, Type 2

2012 (3 papers)

  1. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J, Aggarwal N, Polidori D, et al. · Diabetes Care · 2012 · Derived
    PubMed: PMID 22492586 · NCT00642278 · Diabetes Mellitus, Type 2
  2. Basal insulin and cardiovascular and other outcomes in dysglycemia.
    ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22686416 · NCT02624908 · Diabetes Mellitus, Type 2
  3. Hypoglycemia and risk of death in critically ill patients.
    NICE-SUGAR Study Investigators, Finfer S, Liu B, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22992074 · NCT02624908 · Diabetes Mellitus, Type 2

2011 (3 papers)

  1. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.
    Johnston SS, Conner C, Aagren M, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 21421802 · NCT02624908 · Diabetes Mellitus, Type 2
  2. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
    Home PD, Fritsche A, Schinzel S, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 20649629 · NCT02624908 · Diabetes Mellitus, Type 2
  3. Emergency hospitalizations for adverse drug events in older Americans.
    Budnitz DS, Lovegrove MC, Shehab N, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 22111719 · NCT02624908 · Diabetes Mellitus, Type 2

2010 (4 papers)

  1. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients.
    von Lewinski D, Rainer PP, Gasser R, et al. · Metabolism · 2010 · Background
    PubMed: PMID 20045149 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  2. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.
    March WA, Moore VM, Willson KJ, et al. · Hum Reprod · 2010 · Background
    PubMed: PMID 19910321 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  3. SGLT2 inhibition--a novel strategy for diabetes treatment.
    Chao EC, Henry RR · Nat Rev Drug Discov · 2010 · Background
    PubMed: PMID 20508640 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  4. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.
    Bays H · Curr Med Res Opin · 2010 · Background
    PubMed: PMID 19232040 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

2009 (1 paper)

  1. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease.
    Krenning G, Dankers PY, Drouven JW, et al. · Am J Physiol Renal Physiol · 2009 · Background
    PubMed: PMID 19339628 · NCT02964585 · Diabetes Mellitus, Type 2

2008 (4 papers)

  1. Physical activity assessment with accelerometers: an evaluation against doubly labeled water.
    Plasqui G, Westerterp KR · Obesity (Silver Spring) · 2008 · Background
    PubMed: PMID 17925461 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  2. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
    Han S, Hagan DL, Taylor JR, et al. · Diabetes · 2008 · Background
    PubMed: PMID 18356408 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  3. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients.
    Ceriello A, Esposito K, Piconi L, et al. · Diabetes · 2008 · Background
    PubMed: PMID 18299315 · NCT02624908 · Diabetes Mellitus, Type 2
  4. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG, Nuber U, Landgraf W, et al. · Lancet · 2008 · Background
    PubMed: PMID 18374840 · NCT02624908 · Diabetes Mellitus, Type 2

2007 (6 papers)

  1. The management of insulin resistance in polycystic ovary syndrome.
    Teede HJ, Hutchison SK, Zoungas S, et al. · Trends Endocrinol Metab · 2007 · Background
    PubMed: PMID 17698366 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  2. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes.
    Rask-Madsen C, King GL · Nat Clin Pract Endocrinol Metab · 2007 · Background
    PubMed: PMID 17179929 · NCT02964585 · Diabetes Mellitus, Type 2
  3. Actigraph accelerometer interinstrument reliability during free-living in adults.
    McClain JJ, Sisson SB, Tudor-Locke C, et al. · Med Sci Sports Exerc · 2007 · Background
    PubMed: PMID 17805082 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  4. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
    Losordo DW, Schatz RA, White CJ, et al. · Circulation · 2007 · Background
    PubMed: PMID 17562958 · NCT02964585 · Diabetes Mellitus, Type 2
  5. The validation of a novel activity monitor in the measurement of posture and motion during everyday activities.
    Grant PM, Ryan CG, Tigbe WW, et al. · Br J Sports Med · 2007 · Background
    PubMed: PMID 16980531 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  6. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.
    Azziz R, Carmina E, Dewailly D, et al. · J Clin Endocrinol Metab · 2007 · Background
    PubMed: PMID 16940456 · NCT06256289 · Non-alcoholic Fatty Liver Disease

2006 (3 papers)

  1. The changes of metabolic profile and weight during Ramadan fasting.
    Ziaee V, Razaei M, Ahmadinejad Z, et al. · Singapore Med J · 2006 · Background
    PubMed: PMID 16645692 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  2. Determination of cardiac volumes and mass with FLASH and SSFP cine sequences at 1.5 vs. 3 Tesla: a validation study.
    Hudsmith LE, Petersen SE, Tyler DJ, et al. · J Magn Reson Imaging · 2006 · Background
    PubMed: PMID 16795076 · NCT05367063 (CANA-DIA-FIB) · Diabetes Mellitus, Type 2
  3. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications.
    Brownlee M, Hirsch IB · JAMA · 2006 · Background
    PubMed: PMID 16609094 · NCT02624908 · Diabetes Mellitus, Type 2

2005 (5 papers)

  1. Circulating endothelial progenitor cells and cardiovascular outcomes.
    Werner N, Kosiol S, Schiegl T, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16148285 · NCT02964585 · Diabetes Mellitus, Type 2
  2. Gene transfer in endothelial dysfunction and hypertension.
    Sen S, Strappe PM, O'Brien T, et al. · Methods Mol Med · 2005 · Background
    PubMed: PMID 16028691 · NCT02964585 · Diabetes Mellitus, Type 2
  3. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study.
    Salti I, Bénard E, Detournay B, et al. · Diabetes Care · 2005 · Background
    PubMed: PMID 15451892 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2
  4. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
    Meyer C, McGrath BP, Teede HJ, et al. · J Clin Endocrinol Metab · 2005 · Background
    PubMed: PMID 16046590 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  5. Recommendations for management of diabetes during Ramadan.
    Al-Arouj M, Bouguerra R, Buse J, et al. · Diabetes Care · 2005 · Background
    PubMed: PMID 16123509 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

2004 (2 papers)

  1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group · Fertil Steril · 2004 · Background
    PubMed: PMID 14711538 · NCT06256289 · Non-alcoholic Fatty Liver Disease
  2. High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro.
    Li H, Gu Y, Zhang Y, et al. · J Soc Gynecol Investig · 2004 · Background
    PubMed: PMID 14980308 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

2003 (1 paper)

  1. International physical activity questionnaire: 12-country reliability and validity.
    Craig CL, Marshall AL, Sjöström M, et al. · Med Sci Sports Exerc · 2003 · Background
    PubMed: PMID 12900694 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

2002 (1 paper)

  1. AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat.
    McCrimmon RJ, Evans ML, Jacob RJ, et al. · Am J Physiol Endocrinol Metab · 2002 · Background
    PubMed: PMID 12376337 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

1998 (1 paper)

  1. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.
    King H, Aubert RE, Herman WH, et al. · Diabetes Care · 1998 · Background
    PubMed: PMID 9727886 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

1996 (1 paper)

  1. Glucose transporters in the transepithelial transport of glucose.
    Takata K · J Electron Microsc (Tokyo) · 1996 · Background
    PubMed: PMID 8888584 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

1987 (1 paper)

  1. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
    Rossetti L, Smith D, Shulman GI, et al. · J Clin Invest · 1987 · Background
    PubMed: PMID 3571496 · NCT02694263 (Can Do) · Diabetes Mellitus, Type 2

1985 (1 paper)

  1. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.
    Wild RA, Painter PC, Coulson PB, et al. · J Clin Endocrinol Metab · 1985 · Background
    PubMed: PMID 4044782 · NCT06256289 · Non-alcoholic Fatty Liver Disease

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).